683 related articles for article (PubMed ID: 31328428)
1. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
3. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
4. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
[TBL] [Abstract][Full Text] [Related]
5. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
6. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.
van Vilsteren FG; Baskin-Bey ES; Nagorney DM; Sanderson SO; Kremers WK; Rosen CB; Gores GJ; Hobday TJ
Liver Transpl; 2006 Mar; 12(3):448-56. PubMed ID: 16498656
[TBL] [Abstract][Full Text] [Related]
8. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study.
Abdel-Rahman O; Fazio N
J Neuroendocrinol; 2021 May; 33(5):e12971. PubMed ID: 33870570
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological Characteristics and Survival Outcomes of Primary Hepatic Neuroendocrine Tumor: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study.
Li YF; Zhang QQ; Wang WL
Med Sci Monit; 2020 Jul; 26():e923375. PubMed ID: 32651994
[TBL] [Abstract][Full Text] [Related]
11. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
12. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
13. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
14. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
Fang C; Wang W; Feng X; Sun J; Zhang Y; Zeng Y; Wang J; Chen H; Cai M; Lin J; Chen M; Chen Y; Li Y; Li S; Chen J; Zhou Z
Br J Cancer; 2017 Nov; 117(10):1544-1550. PubMed ID: 28949958
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
16. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
17. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
19. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
20. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
